420 related articles for article (PubMed ID: 20142600)
1. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
Lacouture ME; Mitchell EP; Piperdi B; Pillai MV; Shearer H; Iannotti N; Xu F; Yassine M
J Clin Oncol; 2010 Mar; 28(8):1351-7. PubMed ID: 20142600
[TBL] [Abstract][Full Text] [Related]
2. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
[TBL] [Abstract][Full Text] [Related]
3. STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction.
Coleman S; Jatoi A
Curr Oncol Rep; 2010 Jul; 12(4):223-5. PubMed ID: 20437117
[No Abstract] [Full Text] [Related]
4. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
Kobayashi Y; Komatsu Y; Yuki S; Fukushima H; Sasaki T; Iwanaga I; Uebayashi M; Okuda H; Kusumi T; Miyagishima T; Sogabe S; Tateyama M; Hatanaka K; Tsuji Y; Nakamura M; Konno J; Yamamoto F; Onodera M; Iwai K; Sakata Y; Abe R; Oba K; Sakamoto N
Future Oncol; 2015; 11(4):617-27. PubMed ID: 25686117
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
6. Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.
Nakata K; Komori T; Saso K; Ota H; Kagawa Y; Morita S; Noura S; Hayashi N; Uemura M; Matsuda C; Satoh T; Mizushima T; Murata K; Doki Y; Eguchi H;
Int J Colorectal Dis; 2021 Dec; 36(12):2621-2627. PubMed ID: 34345969
[TBL] [Abstract][Full Text] [Related]
7. Impact of a pre-emptive skin treatment regimen on skin toxicities of anti-epidermal growth factor receptor monoclonal antibodies: more questions than answers.
Rother M
J Clin Oncol; 2010 Sep; 28(27):e474; author reply e475-6. PubMed ID: 20585089
[No Abstract] [Full Text] [Related]
8. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti P; Fargnoli MC; Porzio G; Salvatore L; Filippi R; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Dell'Aquila E; Lombardi P; Keränen SR; Depetris I; Giampieri R; Morelli C; De Tursi M; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Cortellini A; Pensieri MV; Ficorella C; Ferri C; Parisi A
Support Care Cancer; 2022 Mar; 30(3):2455-2465. PubMed ID: 34779921
[TBL] [Abstract][Full Text] [Related]
9. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
11. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Thaler J; Karthaus M; Mineur L; Greil R; Letocha H; Hofheinz R; Fernebro E; Gamelin E; Baños A; Köhne CH
BMC Cancer; 2012 Sep; 12():438. PubMed ID: 23020584
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
13. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.
Bouché O; Ben Abdelghani M; Labourey JL; Triby S; Bensadoun RJ; Jouary T; Des Guetz G
World J Gastroenterol; 2019 Aug; 25(29):4007-4018. PubMed ID: 31413534
[TBL] [Abstract][Full Text] [Related]
14. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
15. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Raimondi A; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Amatu A; Tampellini M; Racca P; Murialdo R; Clavarezza M; Zaniboni A; Toscano G; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Niger M; Antista M; Ambrosini M; Pagani F; Prisciandaro M; Randon G; de Braud F; Di Bartolomeo M; Pietrantonio F; Morano F
Support Care Cancer; 2021 Jul; 29(7):3971-3980. PubMed ID: 33392769
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
17. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
[TBL] [Abstract][Full Text] [Related]
18. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
19. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
Koukakis R; Gatta F; Hechmati G; Siena S
Qual Life Res; 2016 Oct; 25(10):2645-2656. PubMed ID: 27083443
[TBL] [Abstract][Full Text] [Related]
20. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
